Replies to post #17034 on CytoSorbents Corporation (CTSO)

[hemopure36]

More fake news. Other than Dr. Chan, who sold only enough to cover his costs after being granted shares, please tell me who else sold within the last year and provide a link. Bloch (family) purchased shares on the open market. Show me how losses are growing more than revenues, please. There are plenty of reasons to buy shares before two years, in my opinion. We’ll soon see results from the German study, get news that a Hemodefend NDA was filed, get Hemodefend results and hopefully approval sometime next year, potentially see a partner for CRS in CAR-T therapy, see increased sales from substantially more sales people and new countries and more indications for use, will potentially see standard of care designation in Germany or elsewhere, will see more studies on efficacy. I’m in the business and I see enormous potential, which I think will manifest in the share price as we ramp up to all these possibilities. Scared money always loses.

[biotech48]

well slappie you have exaggerated all of the negatives and ignored the positive accomplishments as you usually do. Yes losses are growing faster than revenues but management explained that issue. That they are hiring more direct sales to take over indirect sales areas. That should raise revenue by a lot, shortly. Dr. Chan did sell some shares, but you have seen that explained on this board, like I have, that it was he received more stock options, to cover taxes. He sold a very small amount of what he received. No, it is not two years behind the inflection point, we may be at the inflection point now with record sales this quarter, just won't know for sure until we look back later. What you aren't addressing is the 14% drop in sales price after very good earnings, which I am sure that you are cheering as a short.